US Patent 8,829,005: Claim Scope, Zerviate Coverage, Exclusivity, and Patent Landscape

US Patent 8,829,005 protects a narrow method of treating allergic conjunctivitis with cetirizine ophthalmic solution. Its independent claim requires four central elements: 0.24% w/v cetirizine as the sole active ingredient, twice-daily topical ocular administration, no cyclodextrin, and a specified excipient system at a pH of 6.8 to 7.2. The claim is closely aligned with the commercial formulation of Zerviate, the cetirizine ophthalmic product approved by the FDA for ocular itching associated with allergic conjunctivitis.[1][2]

The patent has strong product-formulation relevance but limited breadth outside the claimed concentration, dosing frequency, excipients, and pH range. A competing product using a different cetirizine concentration, dosing schedule, excipient profile, or pH may avoid literal infringement, subject to prosecution history and doctrine-of-equivalents analysis.

What product does US Patent 8,829,005 protect?

US 8,829,005 protects a treatment method rather than a composition claim standing alone. The protected method involves administration to an eye of a formulation containing:

Required element	Claim requirement
Active ingredient	Cetirizine
Active-ingredient concentration	0.24% w/v
Active-ingredient status	Single active ingredient
Route	Topical administration to an eye
Dosing	Twice daily
Cyclodextrin	Excluded
PEG 400	1%
Dibasic sodium phosphate, anhydrous	0.2%
Hypromellose	0.25%
Polysorbate 80	0.1%
Glycerin	1.8%
Benzalkonium chloride	0.01%
Vehicle	Purified water
pH	6.8 to 7.2
Disease	Allergic conjunctivitis
Treatment objective	Alleviation of a sign or symptom

The claim language substantially tracks the formulation described for Zerviate, whose active ingredient is cetirizine hydrochloride equivalent to cetirizine 0.24%.[1]

How broad is independent claim 1?

Claim 1 is narrow in formulation terms but broad in symptom terms.

Formulation limitations

The formulation must contain the listed excipients at the stated concentrations. The claim does not merely require PEG 400, hypromellose, glycerin, or a phosphate buffer in general. It recites specific concentrations and named pharmacopeial grades.

A formulation containing 0.5% hypromellose instead of 0.25%, for example, would not literally satisfy the claim. The same analysis applies to a product using 0.15% polysorbate 80, a different preservative, or a pH outside 6.8 to 7.2.

The claim also requires the formulation to contain no cyclodextrin. A cetirizine ophthalmic product containing hydroxypropyl-beta-cyclodextrin or another cyclodextrin would fall outside the literal scope of this limitation, even if all other ingredients matched.

Single-active-ingredient limitation

The formulation must have cetirizine as the single active ingredient. This limitation excludes a combination product containing another pharmacologically active ophthalmic ingredient, such as an antihistamine-mast-cell stabilizer combination, a corticosteroid, or a decongestant.

Inactive ingredients do not defeat the single-active-ingredient limitation. The listed preservative, buffer, surfactant, viscosity agent, humectant, and vehicle are excipients.

Method limitations

The claim requires:

A subject in need of treatment.
Topical administration to an eye.
Twice-daily dosing.
Alleviation of a sign or symptom of allergic conjunctivitis.

A product label recommending once-daily dosing would create a potential noninfringement position against the literal twice-daily limitation. Actual physician-directed use, however, can create separate inducement or contributory-infringement issues if the patent remains enforceable and the relevant use is encouraged or supported by labeling.

What do dependent claims 2 through 8 add?

Does claim 2 broaden the dosage-form coverage?

Claim 2 lists an aqueous formulation, ointment, oil, suspension, emulsion, or drug-delivery device. The claim is unusual because claim 1 already recites a detailed formulation that is most naturally understood as an aqueous ophthalmic solution.

Claim 2 does not remove the limitations of claim 1. As a dependent claim, it incorporates all claim 1 requirements and adds an alternative dosage-form characterization. The listed forms therefore do not automatically authorize a formulation that omits the claim 1 excipients or pH range.

The practical value of claim 2 is limited. It attempts to preserve coverage across multiple delivery formats, but the detailed composition limitations in claim 1 constrain the actual scope.

What symptoms are covered by claims 3 through 8?

Claim	Covered sign, symptom, or condition
3	Itching
4	Ocular itching, ocular redness, and lid swelling
5	Severe ocular itching, severe ocular redness, or severe lid swelling
6	A composition comfortable upon instillation
7	A nasal sign or symptom
8	Nasal congestion, nasal itching, ear itching, palate itching, or rhinorrhea

Claims 3 through 5 focus on ocular symptoms associated with allergic conjunctivitis. Claims 7 and 8 extend the claimed treatment objective to nasal and related symptoms. These claims do not convert the patent into a broad patent on oral or intranasal cetirizine. Claim 1 still requires topical administration to an eye of the specified ophthalmic formulation.

How meaningful is the comfort limitation in claim 6?

Claim 6 requires that the composition be comfortable upon instillation. This is a functional or subjective limitation. Its enforcement value depends on how “comfortable” is construed and proven. Clinical tolerability data, labeling, patient-reported outcomes, and comparative instillation studies could become relevant.

The limitation may be difficult to use as a stand-alone commercial discriminator because many ophthalmic products are designed to be comfortable. It also creates potential claim-construction disputes over whether comfort is an objective product property, an intended result, or a characteristic that must be demonstrated in the accused product.

What patent protects Zerviate?

Zerviate is the principal commercial product associated with the claimed cetirizine ophthalmic formulation. The FDA approved Zerviate, NDA 210514, in 2017 for the temporary relief of ocular itching associated with allergic conjunctivitis.[1]

US 8,829,005 is one of the key patents associated with the cetirizine ophthalmic product platform. Publicly available patent records identify the patent as covering ophthalmic compositions and methods involving cetirizine.[2] Later patents and patent-family members may cover additional formulation, manufacturing, dosing, or commercial-product characteristics. The existence and scope of those later rights must be evaluated separately from the claims of US 8,829,005.

What is the Orange Book status?

FDA Orange Book listings determine whether a patent is formally listed against an approved drug product for abbreviated new drug application purposes.[3] The relevant product is Zerviate, cetirizine ophthalmic solution 0.24%, NDA 210514.

A patent listed for Zerviate can create an ANDA certification obligation. A generic applicant may be required to submit:

Paragraph I certification, if no patent information is listed;
Paragraph II certification, if the patent has expired;
Paragraph III certification, if the applicant will wait until patent expiration; or
Paragraph IV certification, if the applicant asserts that the patent is invalid, unenforceable, or not infringed.

The patent’s method-of-use character is commercially important. A generic applicant may attempt a section viii “carve-out” for a patented use if the proposed labeling omits the protected indication or use. That route is less straightforward where the listed patent claims the same indication and dosing regimen that define the product’s principal commercial use.

When does US 8,829,005 lose exclusivity?

US 8,829,005 issued on September 9, 2014.[2] The ordinary US patent term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and applicable priority rules.[4]

Public patent databases commonly associate the patent family with a 2027 expiration period. The precise enforceable expiration date should be determined from the USPTO Patent Center record and any applicable patent-term adjustment or terminal disclaimer. FDA regulatory exclusivity is separate from patent exclusivity.

Exclusivity category	Relevant status
FDA approval	Zerviate approved in 2017
New chemical entity exclusivity	Not the principal barrier because cetirizine was previously approved orally
Orphan exclusivity	Not applicable to allergic conjunctivitis
Patent protection	Centered on formulation and method claims
ANDA challenge risk	Depends on Orange Book listing and generic certification
Patent expiry	Generally associated with the 2027 period for US 8,829,005

FDA approval exclusivity for Zerviate is not equivalent to the patent term. A generic may face patent barriers after regulatory exclusivity expires, while a patent may remain enforceable after FDA exclusivity ends.

What generic entry risks exist for Zerviate?

A generic applicant has several potential design-around strategies.

Formulation design-arounds

A competing product could attempt to change one or more of the following:

Cetirizine concentration;
Dosing frequency;
Preservative;
Surfactant;
Buffer system;
Viscosity agent;
Humectant concentration;
pH;
Use of a cyclodextrin;
Use of a different delivery vehicle.

The most direct design-around would use cetirizine at a concentration other than 0.24% w/v or a dosing instruction other than twice daily. That approach may create clinical, regulatory, or labeling limitations because the applicant must still demonstrate safety, efficacy, and pharmaceutical equivalence under the applicable FDA pathway.

Labeling design-arounds

A generic applicant may seek to omit patented indications or dosing instructions through a section viii statement. The feasibility depends on the exact Orange Book listing and whether the remaining label still induces use that practices the patent claims.

For a method claim requiring twice-daily administration, a once-daily label could reduce literal infringement risk. The applicant would still need to evaluate whether physicians are likely to use the product in the patented manner and whether the labeling, promotional materials, or regulatory submission encourages that use.

Invalidity positions

Potential validity issues include:

Written-description support for the exact excipient concentrations;
Enablement of the full range of dosage forms identified in claim 2;
Obviousness based on prior cetirizine formulations and ophthalmic delivery systems;
Indefiniteness of “comfortable upon instillation” in claim 6;
Written-description or enablement questions concerning nasal symptoms under claims 7 and 8;
Scope and support for the “single active ingredient” limitation.

The narrowness of claim 1 can help validity by tying the claim to a specific formulation. It can also make the claim easier to attack if the prior art discloses the same ingredients, concentration, pH, and dosing regimen.

Which companies are relevant to the patent landscape?

Santen and Eyevance

Zerviate was developed and commercialized through the Eyevance and Nicox commercial network. Santen acquired Eyevance and its ophthalmic portfolio, including Zerviate-related commercial interests.[5] Ownership, licensing, and enforcement rights should be separated because the patent assignee, NDA holder, commercial licensee, and litigation plaintiff may not be the same entity.

Generic manufacturers

Likely generic competition would come from manufacturers with ophthalmic solution capabilities and experience filing ANDAs for branded ophthalmic products. The principal commercial barriers are not only the patent claims. They also include:

Establishing pharmaceutical equivalence;
Demonstrating appropriate pH and sterility;
Matching preservative and container-closure performance;
Conducting extractables and leachables studies;
Establishing stability;
Addressing device or drop-delivery performance;
Managing patent certifications and possible litigation.

No biosimilar pathway applies. Cetirizine is a small-molecule drug, so competitive entry would proceed through the ANDA pathway or, in some circumstances, a 505(b)(2) application rather than a biosimilar application.

What patent litigation or Paragraph IV settlements affect this patent?

A Paragraph IV filing can trigger patent litigation under the Hatch-Waxman Act. If the NDA holder or patent owner sues within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court action.

The supplied claim set alone does not establish a Paragraph IV filing, a filed infringement action, or a settlement involving US 8,829,005. The key public sources for verification are FDA’s Orange Book, FDA’s Paragraph IV litigation listings, PACER, and district-court docket records.[3][6]

A settlement could include an agreed generic launch date, a license, restrictions on formulation or labeling, or a covenant not to sue. No settlement term should be inferred from patent ownership or commercial licensing arrangements.

How strong is the patent estate for cetirizine ophthalmic products?

The estate is strongest against a product that copies the commercial Zerviate formulation and labeling:

Risk factor	Assessment
Exact 0.24% cetirizine concentration	High claim overlap
Twice-daily use	High claim overlap
Same excipient concentrations	High claim overlap
pH 6.8-7.2	High claim overlap
No cyclodextrin	High claim overlap
Different pH or excipient system	Potential design-around
Different dosing frequency	Potential design-around
Combination product	Likely outside single-active limitation
Intranasal or oral product	Outside the required ocular administration
Different cetirizine concentration	Potentially outside literal claim scope
Ointment, emulsion, or device	Ambiguous because claim 1’s composition limitations remain

The patent is therefore commercially relevant but not a complete platform monopoly on cetirizine ophthalmic therapy. Its practical strength depends on whether later patents cover alternative formulations and whether the approved product’s regulatory label makes the patented method difficult to omit.

How does US 8,829,005 compare with competing allergy-eye products?

Product or class	Active ingredient	Typical competitive position
Zerviate	Cetirizine 0.24%	Direct cetirizine ophthalmic product
Pataday	Olopatadine	Established antihistamine/mast-cell stabilizer competitor
Lastacaft	Alcaftadine	Once-daily allergy-eye competitor
Zaditor/Alaway	Ketotifen	OTC antihistamine/mast-cell stabilizer products
Oral cetirizine products	Cetirizine	Systemic therapy, not direct claim overlap
Other ophthalmic antihistamines	Various	Alternative mechanism or formulation

The patent does not block these competing active ingredients. Its competitive effect is concentrated on cetirizine ophthalmic products using the claimed formulation and twice-daily regimen.

Key Takeaways

US 8,829,005 is a narrow method patent tied closely to the Zerviate formulation.
Claim 1 requires 0.24% w/v cetirizine, twice-daily ocular administration, no cyclodextrin, specified excipients, and pH 6.8 to 7.2.
Claims 3 through 8 expand the covered symptoms but do not remove the core formulation and administration limitations.
Claim 2’s alternative dosage forms do not clearly eliminate the detailed composition requirements of claim 1.
The patent is relevant to ANDA strategy, Paragraph IV analysis, section viii labeling, and formulation design-around work.
Generic risk is highest for a product that copies Zerviate’s concentration, excipients, pH, and twice-daily use.
No biosimilar pathway applies because cetirizine is a small-molecule drug.
The patent is generally associated with the 2027 expiration period, subject to the official USPTO patent-term record.
Orange Book status and later patent-family rights must be reviewed separately from the claim language provided.
Commercial exclusivity depends on the combined effect of patent claims, regulatory listing, labeling, formulation know-how, and generic approval requirements.

FAQs About US Patent 8,829,005

Does US 8,829,005 cover all cetirizine eye drops?

No. The independent claim requires 0.24% w/v cetirizine, twice-daily use, the specified excipient concentrations, no cyclodextrin, and pH 6.8 to 7.2.

Can a once-daily cetirizine eye drop avoid infringement?

It may avoid literal infringement of the twice-daily limitation, but the complete infringement analysis would also consider induced infringement, labeling, actual use, prosecution history, and equivalents.

Does the patent cover oral cetirizine for allergic conjunctivitis?

No. The claims require topical administration to an eye of the specified ophthalmic formulation.

Is Zerviate eligible for biosimilar competition?

No. Cetirizine is a small molecule. Competition would generally involve an ANDA or potentially a 505(b)(2) application, not a biosimilar application.

Can a product containing cyclodextrin infringe US 8,829,005?

A formulation containing cyclodextrin would not literally satisfy the claim 1 limitation that the formulation does not contain a cyclodextrin. Equivalents analysis could raise a separate issue, but the claim expressly excludes cyclodextrin.

References

U.S. Food and Drug Administration. (2017). Zerviate (cetirizine hydrochloride ophthalmic solution) prescribing information.
U.S. Patent No. 8,829,005. (2014). Ophthalmic compositions comprising cetirizine. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension resources.
Santen Pharmaceutical Co., Ltd. (2020). Santen acquires Eyevance Pharmaceuticals.
U.S. Food and Drug Administration. (n.d.). Paragraph IV patent certifications and litigation information.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Harrow Eye	ZERVIATE	cetirizine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	208694-001	May 30, 2017		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2755679	⤷ Start Trial
European Patent Office	2408453	⤷ Start Trial
European Patent Office	2547340	⤷ Start Trial
European Patent Office	3943069	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,829,005

Which drugs does patent 8,829,005 protect, and when does it expire?

Summary for Patent: 8,829,005